Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{200700,
        author = {Deoraikar Aanushk Nilesh and Bahir Vaibhav Hanumant and Kardile Shivam Limbraj and Dr. Mulye Sagar and Dr. Kolhe Sunil},
        title = {Formulation and Evaluation of Transdermal Patches of Mefenamic acid & Dicyclomine},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {12},
        pages = {1803-1809},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=200700},
        abstract = {Topically applied medications are known as transdermal drug delivery systems (TDDS). One significant issue that causes the transdermal patch to become unstable and reduces medication delivery is the crystallization of mefenamic acid. In order to prevent mefenamic acid from crystallizing, an additive (PVP K90) was utilized. Transdermal patches typically contain two medications, such as mefenamic acid and dicyclomine. The goal of the current study was to create and assess a novel transdermal formulation of dicyclomine and mefenamic acid, which are used to relax muscles and reduce discomfort, particularly during the menstrual cycle. Furthermore, tests on drug permeation and release (drug index) were conducted using Franze diffusion cell membranes and UV visible spectra, respectively.},
        keywords = {TDDS, Transdermal patch, mefenamic acid, dicyclomine, crystallization.},
        month = {May},
        }